| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide, which is a drug for treatment of acromegaly, for a period of at least two months. Ž<P>SOLUTION: This implant formulation is hydrogel containing octreotide, where the hydrogel has a copolymer obtained by copolymerization of a mixture having at least two hydrophilic ethylenic unsaturated monomers, optionally has hydroxypropylcellulose, and contains 20-150 mg of octreotide in a free form or a salt form. The implant releases octreotide in the body of a patient in an amount of 0.1-9 ng/ml in terms of in-vivo average Css for a period of at least two months. Ž<P>COPYRIGHT: (C)2010,JPO&INPIT Ž
|
